PTLA Portola Pharmaceuticals Inc

Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Bill Lis, chief executive officer, will present at the following conferences in March:

• Cowen and Company’s 37th Annual Health Care Conference on Tuesday, March 7, 2017, at 9:20 a.m. Eastern Time in Boston.
• Oppenheimer’s 27th Annual Healthcare Conference on Wednesday, March 22, 2017, at 1:35 p.m. Eastern Time in New York.

Both presentations will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.

About Portola Pharmaceuticals, Inc.Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.

Investor Contact:              
Ana Kapor                               
Portola Pharmaceuticals         
ir@portola.com                  

Media Contact:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087